Samsung Biologics
Sustainability Report and Carbon Intensity Rankings
Is Samsung Biologics doing their part?
Their DitchCarbon score is 40
Samsung Biologics has a DitchCarbon Score of 40 out of 100, indicating moderate performance in sustainability practices. This score reflects the company’s current carbon intensity level, suggesting there is significant room for improvement in reducing emissions. A higher score would demonstrate a stronger commitment to lowering carbon intensity and enhancing overall environmental sustainability.
This was calculated based on 30+ company specific emissions data points, the higher the score, the better. Check out our methodology.
Industry emissions intensity
Very low
Low
Medium
High
Very high
Samsung Biologics is part of the research and development sector, which has a carbon intensity ranking of very low. Some industries are more damaging than others, this ranking gives you an indication of how carbon intensive the industry is which this company operates in.
Location emissions intensity
Very low
Low
Unknown
High
Very high
Samsung Biologics, based in South Korea, operates in a region with a specific carbon intensity rating. The sustainability of the company’s operations is influenced by South Korea’s national efforts to manage its carbon footprint.
Unlock 30+ emissions data points on Samsung Biologics
Get the emissions intelligence you need, no surveys required.
– Historical Scope 1, 2 and 3 emissions
– Coverage of all industries, product level data
– Emissions forecasting, assurances
Unlock 30+ emissions data points on Samsung Biologics
Get the emissions intelligence you need, no surveys required.
– Historical Scope 1, 2 and 3 emissions
– Coverage of all industries, product level data
– Emissions forecasting, assurances
11.36%
...this company is doing 11.36% worse in emissions than the industry average.
Samsung BioLogics, founded in 2011 and headquartered in Incheon, South Korea, operates in the biopharmaceutical industry as a leading Contract Manufacturing Organization (CMO). The company specializes in the research and development, manufacturing, and global distribution of biopharmaceutical products, adhering to stringent cGMP regulations. With a commitment to quality and customer-oriented services, Samsung BioLogics is poised for global expansion, aiming to make a significant impact on healthcare worldwide.
emission intelligence's platform recommendations for Samsung Biologics
Samsung Biologics should consider the implementation of green procurement policies to source low-carbon energy and services, which could potentially reduce their emissions by 0.3%.
Bad news, Samsung Biologics hasn't committed to SBTi goals yet
Samsung Biologics has not yet established specific commitments with the Science Based Targets initiative (SBTi). This means the company is still in the process of defining clear, science-based emissions reduction targets to align with global efforts to mitigate climate change.
Not participating
Claim this profile
Are you associate with this company?
Help us improve our data and claim this profile.
Our methodology
Read about our emission calculation methodologies, and what the DitchCarbon Score means.
Looking for a specific company?
Search our company directory or contact us for custom data requests.